The company, however, continues to work on a phase 1/2 study of its H5 mRNA flu vaccine for pandemic preparedness.

Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.

Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

Its proprietary and differentiated lipid nanoparticle (LNP) platform is a cornerstone in advancing next-generation messenger ...

Moderna, Inc. vs. Novavax, Inc.: cost cuts, vaccine pipeline catalysts, and valuations. Click for this comparison of NVAX and ...

Since the announcements by federal health authorities earlier this year that federal mRNA vaccine funding will be curtailed, a fierce debate has taken place around the future of mRNA-based vaccines ...

Biotech company NTx Bio, also known as Nature’s Toolbox, is pausing its plans for a $31 million manufacturing plant in Plano, ...

Jan 6 (Reuters) - Bayer's Monsanto sued COVID-19 vaccine makers Pfizer, BioNTech and Moderna in Delaware federal court on Tuesday for allegedly misusing its messenger RNA technology in manufacturing ...